精神分裂症谱系障碍患者使用ADHD药物的长期安全性
该研究基于13万余例精神分裂症谱系障碍(SSD)患者,采用个体内Cox回归分析ADHD药物与住院/死亡风险的关系。结果显示,赖右苯丙胺与全因住院/死亡风险降低相关(aHR=0.89),而哌甲酯风险轻度升高(aHR=1.04),且哌甲酯的风险升高仅见于高剂量(≥95 mg/日)或无抗精神病药联用时。总体而言,ADHD药物在SSD患者中的安全性优于通常认知。
要点
- 赖右苯丙胺与SSD患者全因住院/死亡风险降低相关(aHR=0.89,95%CI 0.84-0.94)。
- 哌甲酯高剂量(≥95 mg/日)或无抗精神病药联用时全因住院/死亡风险轻度升高。
- 托莫西汀与精神病性住院风险降低相关(aHR=0.87),赖右苯丙胺与躯体住院风险降低相关(aHR=0.70)。
核心结论
- 在SSD患者中,ADHD药物(尤其赖右苯丙胺所有剂量和低至中剂量长效哌甲酯)的安全性优于通常认知。
研究设计与样本
- 基于N=131,476例SSD患者的队列研究,采用个体内Cox回归分析不同ADHD药物暴露与结局的关联。
主要发现
- 赖右苯丙胺与全因住院/死亡风险降低相关(aHR=0.89,95%CI 0.84-0.94),哌甲酯风险轻度升高(aHR=1.04,95%CI 1.01-1.08)。
- 托莫西汀与精神病性住院风险降低相关(aHR=0.87,95%CI 0.78-0.98),赖右苯丙胺与躯体住院风险降低相关(aHR=0.70,95%CI 0.58-0.84)。
- ADHD多药治疗与躯体住院风险升高相关(aHR=1.37,95%CI 1.07-1.74)。
- 哌甲酯的全因住院/死亡风险升高仅见于剂量≥95 mg/日(aHR=1.08,95%CI 1.03-1.14)或无抗精神病药联用期间(aHR=1.06,95%CI 1.01-1.12)。
- 哌甲酯和赖右苯丙胺的剂量与全因住院/死亡及精神病性住院风险呈U形关联。
临床怎么用
- 对于SSD合并ADHD患者,可考虑使用赖右苯丙胺或低至中剂量长效哌甲酯,并权衡获益与风险。
- 使用哌甲酯时应避免高剂量(≥95 mg/日)并确保与抗精神病药联用,以降低全因住院/死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Attention-deficit hyperactivity disorder (ADHD) is frequently comorbid with schizophrenia spectrum disorders (SSDs) and is associated with poorer outcomes. Yet, its pharmacological treatment in patients with SSDs has been hampered by safety concerns. We therefore examined whether psychiatric, cardiovascular and other medical outcomes are associated with the use of ADHD medications in people with SSDs (N = 131,476). The main outcome was all-cause hospitalization/mortality. Secondary outcomes were hospitalization for psychosis, somatic hospitalization, and cardiovascular hospitalization. Adjusted hazard ratios (aHRs) were calculated for the association between the outcomes and the different exposure categories (compared with non-use of ADHD medication) using within-individual Cox regression analyses. Lisdexamphetamine was associated with a decreased risk of all-cause hospitalization/mortality (aHR = 0.89, 95%CI = 0.84-0.94) and methylphenidate with a slightly increased risk (aHR = 1.04 [1.01-1.08]), while for the other exposures the 95%CI of the HRs encompassed 1. Atomoxetine was associated with a reduced risk of hospitalization for psychosis (aHR = 0.87 [0.78-0.98]), lisdexamphetamine with a reduced risk of somatic hospitalizations (aHR = 0.70 [0.58-0.84]), and ADHD polytherapy with an increased risk of somatic hospitalizations (aHR = 1.37 [1.07-1.74]). No other statistically significant associations were found between the exposures and outcomes (including cardiovascular hospitalizations). Furthermore, increased all-cause hospitalization/mortality risks for methylphenidate were only found with doses ≥95 mgs/day (aHR 1.08 [1.03-1.14]) or during use periods of this agent without concomitant use of an antipsychotic (aHR = 1.06 [1.01-1.12]). Finally, for methylphenidate and lisdexamphetamine, we found evidence of U-shaped associations between doses used and risks of all-cause hospitalization/mortality and psychosis. In conclusion, we find that for people with SSDs, the use of ADHD medication (particularly lisdexamphetamine in all dosages and long-acting methylphenidate in low to medium doses) is safer than generally conceived. The benefits of its use for patients with SSD and comorbid ADHD should therefore be weighed against the risks in a shared decision-making process aimed at improving patients' chances of recovery.
引用
- Luykx JJ, Corbeil O, Kärkkäinen O, et al. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders. Mol Psychiatry. 2025. PMID: 40595332. doi:10.1038/s41380-025-03080-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。